Tiny U.K. Pfizer spinouts start to pop up

A small group of ex-Pfizer ($PFE) employees are launching their own little spinout from the giant R&D complex in Sandwich, which they call a kind of "dating service" for scientists. And they say they are the first of many tiny startups that will launch in the wake of Pfizer's decision to evacuate the drug development hub. "We've certainly learned a lot over the last 5 or 6 months," says Andrew McElroy, the CEO of The Research Network, which will match scientists with biopharma companies. "We've had a lot of help and support as well from government agencies and Pfizer in terms of learning how to set up a new company." Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.